Advertisement

Combined hormonal influence of cyproterone acetate and nomegestrol acetate on meningioma: a case report

  • Pierre-Olivier ChampagneEmail author
  • Thibault Passeri
  • Sebastien Froelich
Case Report - Tumor - Meningioma
  • 39 Downloads
Part of the following topical collections:
  1. Tumor – Meningioma

Abstract

Cyproterone acetate (CPA) is an antiandrogenic drug which has recently been recognized to promote the occurrence and growth of intracranial meningiomas. Nomegestrol acetate (NOMAC) is a widely used progestin-like drug that could be suggested as an alternative for patients taking CPA. We report a case of CPA-related meningioma for which relay from CPA to NOMAC led to further tumor growth and cessation of NOMAC-induced tumor shrinkage. We suggest NOMAC can have a similar effect than CPA on meningiomas. The use of NOMAC as replacement for CPA in the presence of a meningioma should be discouraged until further evidence becomes available on the role of NOMAC in such instances.

Keywords

Cyproterone acetate Nomegestrol acetate Meningioma Hormone therapy 

Notes

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Patient consent

The patient has consented to the submission of the case report for submission to the journal.

References

  1. 1.
    Gil M, Oliva B, Timoner J, Macia MA, Bryant V, de Abajo FJ (2011) Risk of meningioma among users of high doses of cyproterone acetate as compared with the general population: evidence from a population-based cohort study. Br J Clin Pharmacol 72:965–968CrossRefGoogle Scholar
  2. 2.
    Goncalves AM, Page P, Domigo V, Meder JF, Oppenheim C (2010) Abrupt regression of a meningioma after discontinuation of cyproterone treatment. AJNR Am J Neuroradiol 31:1504–1505CrossRefGoogle Scholar
  3. 3.
    Bernat AL, Oyama K, Hamdi S, Mandonnet E, Vexiau D, Pocard M, George B, Froelich S (2015) Growth stabilization and regression of meningiomas after discontinuation of cyproterone acetate: a case series of 12 patients. Acta Neurochir 157:1741–1746CrossRefGoogle Scholar
  4. 4.
    Huang Q, Chen X, Zhu Y, Cao L, Riviere JE (2015) Pharmacokinetics, tissue distribution, and excretion of nomegestrol acetate in female rats. Eur J Drug Metab Pharmacokinet 40:435–442CrossRefGoogle Scholar
  5. 5.
    Yang LP, Plosker GL (2012) Nomegestrol acetate/estradiol: in oral contraception. Drugs 72:1917–1928CrossRefGoogle Scholar
  6. 6.
    Wiemels J, Wrensch M, Claus EB (2010) Epidemiology and etiology of meningioma. J Neuro-Oncol 99:307–314CrossRefGoogle Scholar
  7. 7.
    O’Shea T, Crowley RK, Farrell M, MacNally S, Govender P, Feeney J, Gibney J, Sherlock M (2016) Growth of a progesterone receptor-positive meningioma in a female patient with congenital adrenal hyperplasia. Endocrinol Diabetes Metab Case Rep 2016:16–0054Google Scholar
  8. 8.
    Heijboer AC, Netelenbos JC, Blankenstein MA (2009) Meningioma in untreated congenital adrenal hyperplasia: a relationship? J Neuro-Oncol 92:223–225CrossRefGoogle Scholar
  9. 9.
    Li X, Zhao J (2009) Intracranial meningiomas of childhood and adolescence: report of 34 cases with follow-up. Childs Nerv Syst 25:1411–1417CrossRefGoogle Scholar
  10. 10.
    Jhawar BS, Fuchs CS, Colditz GA, Stampfer MJ (2003) Sex steroid hormone exposures and risk for meningioma. J Neurosurg 99:848–853CrossRefGoogle Scholar
  11. 11.
    Seliger C, Meier CR, Becker C, Jick SS, Proescholdt M, Bogdahn U, Hau P, Leitzmann MF (2017) Metabolic syndrome in relation to risk of meningioma. Oncotarget 8:2284–2292CrossRefGoogle Scholar
  12. 12.
    Shao C, Bai LP, Qi ZY, Hui GZ, Wang Z (2014) Overweight, obesity and meningioma risk: a meta-analysis. PLoS One 9:e90167CrossRefGoogle Scholar
  13. 13.
    Koper JW, Lamberts SW (1994) Meningiomas, epidermal growth factor and progesterone. Hum Reprod (Oxford, England) 9(Suppl 1):190–194CrossRefGoogle Scholar
  14. 14.
    Guay DR (2009) Drug treatment of paraphilic and nonparaphilic sexual disorders. Clin Ther 31:1–31CrossRefGoogle Scholar
  15. 15.
    Neumann F, Berswordt-Wallrabe RV, Elger W, Steinbeck H, Hahn JD, Kramer M (1970) Aspects of androgen-dependent events as studied by antiandrogens. Recent Prog Horm Res 26:337–410Google Scholar
  16. 16.
    Froelich S, Dali-Youcef N, Boyer P, Kehrli P, Maitrot D, Auwerx J (2008) Does cyproterone acetate promote multiple meningiomas? 10th European Congress of Endocrinology, vol 16 Berlin, 158Google Scholar
  17. 17.
    Lello S (2010) Nomegestrol acetate: pharmacology, safety profile and therapeutic efficacy. Drugs 70:541–559CrossRefGoogle Scholar
  18. 18.
    Mueck AO, Sitruk-Ware R (2011) Nomegestrol acetate, a novel progestogen for oral contraception. Steroids 76:531–539CrossRefGoogle Scholar
  19. 19.
    Durmaz R, Deliorman S, Isiksoy S, Uyar R, Tel E (1999) Luteinizing hormone releasing hormone increases proliferation of meningioma cells in vitro. Arch Physiol Biochem 107:286–291Google Scholar
  20. 20.
    Lee KL, Terris MK (2003) Luteinizing hormone-releasing hormone agonists and meningioma: a treatment dilemma. Urology 62:351Google Scholar
  21. 21.
    Cottin V, Vukusic S, Jouanneau E, Lazor R, Cordier J-F (2004) Should patients with lymphangioleiomyomatosis undergo screening for meningioma? Eur Respir J 24:888–889CrossRefGoogle Scholar
  22. 22.
    Raudrant D, Rabe T (2003) Progestogens with antiandrogenic properties. Drugs 63:463–492CrossRefGoogle Scholar
  23. 23.
    Shimizu J, Matsumoto M, Yamazaki E, Yasue M (2008) Spontaneous regression of an asymptomatic meningioma associated with discontinuation of progesterone agonist administration. Neurol Med Chir (Tokyo) 48:227–230CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Austria, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Neurosurgery, Hôpital LariboisièreParis VII-Diderot UniversityParisFrance
  2. 2.Department of Neurosurgery, Lariboisière HospitalUniversity of Paris DiderotParisFrance

Personalised recommendations